Published • loading... • Updated
Anvisa Approves Higher Dose of the Obesity Drug Wegovy.
Summary by Poder360
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Brazil's National Health Surveillance Agency (Anvisa) approved on Monday (May 4, 2026) a new dosage for the drug Wegovy (semaglutide), manufactured by Novo Nordisk. The agency authorized a maintenance dose of up to 7.2 mg per week for the treatment of adults with obesity. This should be combined with a low-calorie diet and physical exercise. The new dosage does not replace the current standard of treatment. It was approved as an "exceptional opt…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
